A bibliometric and visualized analysis of CAR-T or TCR-T in solid tumor (from 2015 to 2024)

This bibliometric analysis examines CAR-T and TCR-T therapies in solid tumors from 2015 to 2024. Solid tumors represent 90% of cancers, posing challenges like complex microenvironments and drug resistance. CAR-T and TCR-T therapies show promise but face issues such as antigen availability and immunosuppression. Using the Web of Science, we identified 989 articles, revealing a significant research increase, especially from 2023 to 2024 (an annual growth rate of 39.9% from 2023 to 2024). The United States and China were the leading contributors, with strong global collaborations. Key institutions included the University of Pennsylvania and Sun Yat-sen University. Co-citation analysis highlighted seminal works by O'Rourke et al. (Sci Transl Med 9(399):eaaa0984, 2017 https://doi.org/10.1126/scitranslmed.aaa0984 ) and Brown et al. (N Engl J Med 375(26):2561–9, 2016 https://doi.org/10.1126/scitranslmed.aaa0984 ). Emerging research foci included nanoparticles, gene editing, and combination therapies. This study underscores rapid progress and global cooperation in this field, providing insights for future research directions.